Gestational diabetes can be defined as a type of diabetes that affects pregnant women.?It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby.?However, there are possibilities that diabetes may return in the later stages of life as type II diabetes mellitus.?It is the inability of insulin to absorb the sugars consumed as part of the meal.?It may be caused due to insulin resistance in a woman s body because of increasing levels of placental hormones being produced to sustain the development of the fetus.?This condition starts when the female body is not able to make and use required amounts of insulin needed in pregnancy, resulting in a build-up of sugar in the bloodstream causing hyperglycemia.
This report aims to provide a comprehensive presentation of the global market for Gestational Diabetes Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gestational Diabetes Treatment. This report contains market size and forecasts of Gestational Diabetes Treatment in global, including the following market information:
Global Gestational Diabetes Treatment Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The global Gestational Diabetes Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Insulin Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Gestational Diabetes Treatment include Biocon Limited, Eli Lilly, Novo Nordisk, Boehringer Ingelheim GmbH, Sanofi S.A., Sun Pharmaceutical Industries Limited, Merck, Novartis and Adocia, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Gestational Diabetes Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Gestational Diabetes Treatment Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Gestational Diabetes Treatment Market Segment Percentages, by Type, 2022 (%)
Insulin
SGLT-2 Inhibitors
Alpha-glucosidase Inhibitors
Others
Global Gestational Diabetes Treatment Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Gestational Diabetes Treatment Market Segment Percentages, by Application, 2022 (%)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Gestational Diabetes Treatment Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Gestational Diabetes Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Gestational Diabetes Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Gestational Diabetes Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biocon Limited
Eli Lilly
Novo Nordisk
Boehringer Ingelheim GmbH
Sanofi S.A.
Sun Pharmaceutical Industries Limited
Merck
Novartis
Adocia
Peptron
AstraZeneca plc
Pfizer, Inc
Takeda Pharmaceutical Company Ltd
Abbott
Antares Pharma
INJEX Pharma AG
Daiichi Sankyo
Outline of Major Chapters:
Chapter 1: Introduces the definition of Gestational Diabetes Treatment, market overview.
Chapter 2: Global Gestational Diabetes Treatment market size in revenue.
Chapter 3: Detailed analysis of Gestational Diabetes Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gestational Diabetes Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Gestational Diabetes Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Gestational Diabetes Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Gestational Diabetes Treatment Overall Market Size
2.1 Global Gestational Diabetes Treatment Market Size: 2022 VS 2032
2.2 Global Gestational Diabetes Treatment Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Gestational Diabetes Treatment Players in Global Market
3.2 Top Global Gestational Diabetes Treatment Companies Ranked by Revenue
3.3 Global Gestational Diabetes Treatment Revenue by Companies
3.4 Top 3 and Top 5 Gestational Diabetes Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Gestational Diabetes Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Gestational Diabetes Treatment Players in Global Market
3.6.1 List of Global Tier 1 Gestational Diabetes Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Gestational Diabetes Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Gestational Diabetes Treatment Market Size Markets, 2022 & 2032
4.1.2 Insulin
4.1.3 SGLT-2 Inhibitors
4.1.4 Alpha-glucosidase Inhibitors
4.1.5 Others
4.2 By Type - Global Gestational Diabetes Treatment Revenue & Forecasts
4.2.1 By Type - Global Gestational Diabetes Treatment Revenue, 2018-2023
4.2.2 By Type - Global Gestational Diabetes Treatment Revenue, 2024-2032
4.2.3 By Type - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Gestational Diabetes Treatment Market Size, 2022 & 2032
5.1.2 Hospital Pharmacies
5.1.3 Retail Pharmacies
5.1.4 Online Pharmacies
5.2 By Application - Global Gestational Diabetes Treatment Revenue & Forecasts
5.2.1 By Application - Global Gestational Diabetes Treatment Revenue, 2018-2023
5.2.2 By Application - Global Gestational Diabetes Treatment Revenue, 2024-2032
5.2.3 By Application - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Gestational Diabetes Treatment Market Size, 2022 & 2032
6.2 By Region - Global Gestational Diabetes Treatment Revenue & Forecasts
6.2.1 By Region - Global Gestational Diabetes Treatment Revenue, 2018-2023
6.2.2 By Region - Global Gestational Diabetes Treatment Revenue, 2024-2032
6.2.3 By Region - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Gestational Diabetes Treatment Revenue, 2018-2032
6.3.2 US Gestational Diabetes Treatment Market Size, 2018-2032
6.3.3 Canada Gestational Diabetes Treatment Market Size, 2018-2032
6.3.4 Mexico Gestational Diabetes Treatment Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Gestational Diabetes Treatment Revenue, 2018-2032
6.4.2 Germany Gestational Diabetes Treatment Market Size, 2018-2032
6.4.3 France Gestational Diabetes Treatment Market Size, 2018-2032
6.4.4 U.K. Gestational Diabetes Treatment Market Size, 2018-2032
6.4.5 Italy Gestational Diabetes Treatment Market Size, 2018-2032
6.4.6 Russia Gestational Diabetes Treatment Market Size, 2018-2032
6.4.7 Nordic Countries Gestational Diabetes Treatment Market Size, 2018-2032
6.4.8 Benelux Gestational Diabetes Treatment Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Gestational Diabetes Treatment Revenue, 2018-2032
6.5.2 China Gestational Diabetes Treatment Market Size, 2018-2032
6.5.3 Japan Gestational Diabetes Treatment Market Size, 2018-2032
6.5.4 South Korea Gestational Diabetes Treatment Market Size, 2018-2032
6.5.5 Southeast Asia Gestational Diabetes Treatment Market Size, 2018-2032
6.5.6 India Gestational Diabetes Treatment Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Gestational Diabetes Treatment Revenue, 2018-2032
6.6.2 Brazil Gestational Diabetes Treatment Market Size, 2018-2032
6.6.3 Argentina Gestational Diabetes Treatment Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Gestational Diabetes Treatment Revenue, 2018-2032
6.7.2 Turkey Gestational Diabetes Treatment Market Size, 2018-2032
6.7.3 Israel Gestational Diabetes Treatment Market Size, 2018-2032
6.7.4 Saudi Arabia Gestational Diabetes Treatment Market Size, 2018-2032
6.7.5 UAE Gestational Diabetes Treatment Market Size, 2018-2032
7 Gestational Diabetes Treatment Companies Profiles
7.1 Biocon Limited
7.1.1 Biocon Limited Company Summary
7.1.2 Biocon Limited Business Overview
7.1.3 Biocon Limited Gestational Diabetes Treatment Major Product Offerings
7.1.4 Biocon Limited Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.1.5 Biocon Limited Key News & Latest Developments
7.2 Eli Lilly
7.2.1 Eli Lilly Company Summary
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Gestational Diabetes Treatment Major Product Offerings
7.2.4 Eli Lilly Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.2.5 Eli Lilly Key News & Latest Developments
7.3 Novo Nordisk
7.3.1 Novo Nordisk Company Summary
7.3.2 Novo Nordisk Business Overview
7.3.3 Novo Nordisk Gestational Diabetes Treatment Major Product Offerings
7.3.4 Novo Nordisk Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.3.5 Novo Nordisk Key News & Latest Developments
7.4 Boehringer Ingelheim GmbH
7.4.1 Boehringer Ingelheim GmbH Company Summary
7.4.2 Boehringer Ingelheim GmbH Business Overview
7.4.3 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Major Product Offerings
7.4.4 Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.4.5 Boehringer Ingelheim GmbH Key News & Latest Developments
7.5 Sanofi S.A.
7.5.1 Sanofi S.A. Company Summary
7.5.2 Sanofi S.A. Business Overview
7.5.3 Sanofi S.A. Gestational Diabetes Treatment Major Product Offerings
7.5.4 Sanofi S.A. Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.5.5 Sanofi S.A. Key News & Latest Developments
7.6 Sun Pharmaceutical Industries Limited
7.6.1 Sun Pharmaceutical Industries Limited Company Summary
7.6.2 Sun Pharmaceutical Industries Limited Business Overview
7.6.3 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Major Product Offerings
7.6.4 Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.6.5 Sun Pharmaceutical Industries Limited Key News & Latest Developments
7.7 Merck
7.7.1 Merck Company Summary
7.7.2 Merck Business Overview
7.7.3 Merck Gestational Diabetes Treatment Major Product Offerings
7.7.4 Merck Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.7.5 Merck Key News & Latest Developments
7.8 Novartis
7.8.1 Novartis Company Summary
7.8.2 Novartis Business Overview
7.8.3 Novartis Gestational Diabetes Treatment Major Product Offerings
7.8.4 Novartis Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.8.5 Novartis Key News & Latest Developments
7.9 Adocia
7.9.1 Adocia Company Summary
7.9.2 Adocia Business Overview
7.9.3 Adocia Gestational Diabetes Treatment Major Product Offerings
7.9.4 Adocia Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.9.5 Adocia Key News & Latest Developments
7.10 Peptron
7.10.1 Peptron Company Summary
7.10.2 Peptron Business Overview
7.10.3 Peptron Gestational Diabetes Treatment Major Product Offerings
7.10.4 Peptron Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.10.5 Peptron Key News & Latest Developments
7.11 AstraZeneca plc
7.11.1 AstraZeneca plc Company Summary
7.11.2 AstraZeneca plc Business Overview
7.11.3 AstraZeneca plc Gestational Diabetes Treatment Major Product Offerings
7.11.4 AstraZeneca plc Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.11.5 AstraZeneca plc Key News & Latest Developments
7.12 Pfizer, Inc
7.12.1 Pfizer, Inc Company Summary
7.12.2 Pfizer, Inc Business Overview
7.12.3 Pfizer, Inc Gestational Diabetes Treatment Major Product Offerings
7.12.4 Pfizer, Inc Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.12.5 Pfizer, Inc Key News & Latest Developments
7.13 Takeda Pharmaceutical Company Ltd
7.13.1 Takeda Pharmaceutical Company Ltd Company Summary
7.13.2 Takeda Pharmaceutical Company Ltd Business Overview
7.13.3 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Major Product Offerings
7.13.4 Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.13.5 Takeda Pharmaceutical Company Ltd Key News & Latest Developments
7.14 Abbott
7.14.1 Abbott Company Summary
7.14.2 Abbott Business Overview
7.14.3 Abbott Gestational Diabetes Treatment Major Product Offerings
7.14.4 Abbott Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.14.5 Abbott Key News & Latest Developments
7.15 Antares Pharma
7.15.1 Antares Pharma Company Summary
7.15.2 Antares Pharma Business Overview
7.15.3 Antares Pharma Gestational Diabetes Treatment Major Product Offerings
7.15.4 Antares Pharma Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.15.5 Antares Pharma Key News & Latest Developments
7.16 INJEX Pharma AG
7.16.1 INJEX Pharma AG Company Summary
7.16.2 INJEX Pharma AG Business Overview
7.16.3 INJEX Pharma AG Gestational Diabetes Treatment Major Product Offerings
7.16.4 INJEX Pharma AG Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.16.5 INJEX Pharma AG Key News & Latest Developments
7.17 Daiichi Sankyo
7.17.1 Daiichi Sankyo Company Summary
7.17.2 Daiichi Sankyo Business Overview
7.17.3 Daiichi Sankyo Gestational Diabetes Treatment Major Product Offerings
7.17.4 Daiichi Sankyo Gestational Diabetes Treatment Revenue in Global Market (2018-2023)
7.17.5 Daiichi Sankyo Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Gestational Diabetes Treatment Market Opportunities & Trends in Global Market
Table 2. Gestational Diabetes Treatment Market Drivers in Global Market
Table 3. Gestational Diabetes Treatment Market Restraints in Global Market
Table 4. Key Players of Gestational Diabetes Treatment in Global Market
Table 5. Top Gestational Diabetes Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Gestational Diabetes Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Gestational Diabetes Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Gestational Diabetes Treatment Product Type
Table 9. List of Global Tier 1 Gestational Diabetes Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Gestational Diabetes Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Gestational Diabetes Treatment Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Gestational Diabetes Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Gestational Diabetes Treatment Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Gestational Diabetes Treatment Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Gestational Diabetes Treatment Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Gestational Diabetes Treatment Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Gestational Diabetes Treatment Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Gestational Diabetes Treatment Revenue, (US$, Mn), 2024-2032
Table 30. Biocon Limited Company Summary
Table 31. Biocon Limited Gestational Diabetes Treatment Product Offerings
Table 32. Biocon Limited Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Biocon Limited Key News & Latest Developments
Table 34. Eli Lilly Company Summary
Table 35. Eli Lilly Gestational Diabetes Treatment Product Offerings
Table 36. Eli Lilly Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lilly Key News & Latest Developments
Table 38. Novo Nordisk Company Summary
Table 39. Novo Nordisk Gestational Diabetes Treatment Product Offerings
Table 40. Novo Nordisk Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Novo Nordisk Key News & Latest Developments
Table 42. Boehringer Ingelheim GmbH Company Summary
Table 43. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Product Offerings
Table 44. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. Boehringer Ingelheim GmbH Key News & Latest Developments
Table 46. Sanofi S.A. Company Summary
Table 47. Sanofi S.A. Gestational Diabetes Treatment Product Offerings
Table 48. Sanofi S.A. Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. Sanofi S.A. Key News & Latest Developments
Table 50. Sun Pharmaceutical Industries Limited Company Summary
Table 51. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Product Offerings
Table 52. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Sun Pharmaceutical Industries Limited Key News & Latest Developments
Table 54. Merck Company Summary
Table 55. Merck Gestational Diabetes Treatment Product Offerings
Table 56. Merck Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Merck Key News & Latest Developments
Table 58. Novartis Company Summary
Table 59. Novartis Gestational Diabetes Treatment Product Offerings
Table 60. Novartis Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 61. Novartis Key News & Latest Developments
Table 62. Adocia Company Summary
Table 63. Adocia Gestational Diabetes Treatment Product Offerings
Table 64. Adocia Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 65. Adocia Key News & Latest Developments
Table 66. Peptron Company Summary
Table 67. Peptron Gestational Diabetes Treatment Product Offerings
Table 68. Peptron Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 69. Peptron Key News & Latest Developments
Table 70. AstraZeneca plc Company Summary
Table 71. AstraZeneca plc Gestational Diabetes Treatment Product Offerings
Table 72. AstraZeneca plc Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 73. AstraZeneca plc Key News & Latest Developments
Table 74. Pfizer, Inc Company Summary
Table 75. Pfizer, Inc Gestational Diabetes Treatment Product Offerings
Table 76. Pfizer, Inc Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 77. Pfizer, Inc Key News & Latest Developments
Table 78. Takeda Pharmaceutical Company Ltd Company Summary
Table 79. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Product Offerings
Table 80. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 81. Takeda Pharmaceutical Company Ltd Key News & Latest Developments
Table 82. Abbott Company Summary
Table 83. Abbott Gestational Diabetes Treatment Product Offerings
Table 84. Abbott Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 85. Abbott Key News & Latest Developments
Table 86. Antares Pharma Company Summary
Table 87. Antares Pharma Gestational Diabetes Treatment Product Offerings
Table 88. Antares Pharma Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 89. Antares Pharma Key News & Latest Developments
Table 90. INJEX Pharma AG Company Summary
Table 91. INJEX Pharma AG Gestational Diabetes Treatment Product Offerings
Table 92. INJEX Pharma AG Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 93. INJEX Pharma AG Key News & Latest Developments
Table 94. Daiichi Sankyo Company Summary
Table 95. Daiichi Sankyo Gestational Diabetes Treatment Product Offerings
Table 96. Daiichi Sankyo Gestational Diabetes Treatment Revenue (US$, Mn) & (2018-2023)
Table 97. Daiichi Sankyo Key News & Latest Developments
List of Figures
Figure 1. Gestational Diabetes Treatment Segment by Type in 2022
Figure 2. Gestational Diabetes Treatment Segment by Application in 2022
Figure 3. Global Gestational Diabetes Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Gestational Diabetes Treatment Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Gestational Diabetes Treatment Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Gestational Diabetes Treatment Revenue in 2022
Figure 8. By Type - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 9. By Application - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 10. By Type - Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 12. By Application - Global Gestational Diabetes Treatment Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 14. By Region - Global Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 15. By Country - North America Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 16. US Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 20. Germany Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 21. France Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 28. China Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 32. India Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 34. Brazil Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Gestational Diabetes Treatment Revenue Market Share, 2018-2032
Figure 37. Turkey Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Gestational Diabetes Treatment Revenue, (US$, Mn), 2018-2032
Figure 41. Biocon Limited Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lilly Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Novo Nordisk Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Boehringer Ingelheim GmbH Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Sanofi S.A. Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Sun Pharmaceutical Industries Limited Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Merck Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Novartis Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Adocia Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Peptron Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. AstraZeneca plc Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Pfizer, Inc Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Takeda Pharmaceutical Company Ltd Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Abbott Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Antares Pharma Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. INJEX Pharma AG Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Daiichi Sankyo Gestational Diabetes Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
